Rapid, label-free, electrical whole blood bioassay based on nanobiosensor systems.

Biomarker detection based on nanowire biosensors has attracted a significant amount of research effort in recent years. However, only very limited research work has been directed toward biomarker detection directly from physiological fluids mainly because of challenges caused by the complexity of media. This limitation significantly reduces the practical impact generated by the aforementioned nanobiosensors. In this study, we demonstrate an In(2)O(3) nanowire-based biosensing system that is capable of performing rapid, label-free, electrical detection of cancer biomarkers directly from human whole blood collected by a finger prick. Passivating the nanowire surface successfully blocked the signal induced by nonspecific binding when performing active measurement in whole blood. Passivated devices showed markedly smaller signals induced by nonspecific binding of proteins and other biomaterials in serum and higher sensitivity to target biomarkers than bare devices. The detection limit of passivated sensors for biomarkers in whole blood was similar to the detection limit for the same analyte in purified buffer solutions at the same ionic strength, suggesting minimal decrease in device performance in the complex media. We then demonstrated detection of multiple cancer biomarkers with high reliability at clinically meaningful concentrations from whole blood collected by a finger prick using this sensing system.

[1]  E. Diamandis,et al.  Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel , 2008, British Journal of Cancer.

[2]  R. Ozols,et al.  CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers , 2009, Cancer.

[3]  Mårten Fernö,et al.  Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. , 2008, European journal of cancer.

[4]  Alexia Iasonos,et al.  CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. , 2007, Gynecologic oncology.

[5]  Chao Li,et al.  Data Storage Studies on Nanowire Transistors with Self-Assembled Porphyrin Molecules , 2004, The Journal of Physical Chemistry B.

[6]  Chao Li,et al.  Nanowire transistors with ferroelectric gate dielectrics: Enhanced performance and memory effects , 2004 .

[7]  C. Zhou,et al.  Synthesis, Electronic Properties, and Applications of Indium Oxide Nanowires , 2003, Annals of the New York Academy of Sciences.

[8]  J. Marks,et al.  Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer , 2008, Breast Cancer Research.

[9]  Sanjib Basu,et al.  Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  H. Kato,et al.  Clinical‐scale high‐throughput human plasma proteome analysis: Lung adenocarcinoma , 2005, Proteomics.

[11]  M. Steinitz,et al.  Quantitation of the blocking effect of tween 20 and bovine serum albumin in ELISA microwells. , 2000, Analytical biochemistry.

[12]  Anderson Nl,et al.  Therapeutic potential of the plasma proteome. , 2003 .

[13]  Mark E. Thompson,et al.  Label-free, electrical detection of the SARS virus N-protein with nanowire biosensors utilizing antibody mimics as capture probes. , 2009, ACS nano.

[14]  M. Passaro,et al.  Comparative evaluation of standard criteria and CA-125 in ovarian cancers treated with platinum or paclitaxel. , 2005, European journal of gynaecological oncology.

[15]  Booncharoen Wongkittisuksa,et al.  Comparison of surface plasmon resonance and capacitive immunosensors for cancer antigen 125 detection in human serum samples. , 2009, Biosensors & bioelectronics.

[16]  M. Lee,et al.  Linker-free directed assembly of high-performance integrated devices based on nanotubes and nanowires , 2006, Nature nanotechnology.

[17]  Chao Li,et al.  Complementary detection of prostate-specific antigen using In2O3 nanowires and carbon nanotubes. , 2005, Journal of the American Chemical Society.

[18]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[19]  C. Zhou,et al.  Tuning electronic properties of In2O3 nanowires by doping control , 2004 .

[20]  N Leigh Anderson,et al.  Therapeutic potential of the plasma proteome. , 2003, Current opinion in molecular therapeutics.

[21]  C. Li,et al.  Chemical gating of In2O3 nanowires by organic and biomolecules , 2003 .

[22]  Irving Langmuir,et al.  The constitution and fundamental properties of solids and liquids. Part II.—Liquids , 1917 .

[23]  Mark A. Reed,et al.  Label-free biomarker detection from whole blood , 2010 .

[24]  Arnaud Buhot,et al.  On the hybridization isotherms of DNA microarrays: the Langmuir model and its extensions , 2006 .

[25]  Chao Li,et al.  charge storage behavior of nanowire transistors functionalized with bis(terpyridine)-Fe(II) molecules: dependence on molecular structure. , 2004, Journal of the American Chemical Society.

[26]  Gengfeng Zheng,et al.  Multiplexed electrical detection of cancer markers with nanowire sensor arrays , 2005, Nature Biotechnology.

[27]  Kang L. Wang,et al.  One-dimensional transport of In2O3 nanowires , 2005 .

[28]  Po-Chiang Chen,et al.  A calibration method for nanowire biosensors to suppress device-to-device variation. , 2009, ACS nano.

[29]  N. Kamata,et al.  Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy , 2007, Oncogene.

[30]  C. Li,et al.  Selective functionalization of In2O3 nanowire mat devices for biosensing applications. , 2005, Journal of the American Chemical Society.

[31]  S. Linder,et al.  Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy , 2007, Clinical Cancer Research.